In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation

Data from Phase 3 ARISTOTLE trial pre-specified subanalysis published in the European Heart Journal PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced results of a... Biopharmaceuticals, CardiologyBristol-Myers Squibb, Pfizer, Eliquis, apixaban, atrial fibrillation, stroke
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news